(Pacmilimab)Biosimilar Reference Antibody-GS40526 新品

货号：GS40526

Pacmilimab is an investigational monoclonal antibody of the IgG4‑kappa isotype that specifically targets programmed death‑ligand 1 (PD‑L1, CD274), an immune checkpoint protein. As an IgG4 isotype, it is engineered to minimize effector functions (e.g., antibody‑dependent cellular cytotoxicity) and focus on checkpoint blockade. By binding to PD‑L1 with high affinity, pacmilimab blocks its interaction with the PD‑1 receptor on T cells, thereby reversing PD‑1/PD‑L1‑mediated immunosuppression and restoring anti‑tumor T‑cell activity. It is being developed as an immune checkpoint inhibitor for the treatment of advanced solid tumors.